Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565494 · ClinicalTrials.gov registry record · Early Phase 1
MDMA-Assisted Therapy for Pathological Narcissism
A Early Phase 1 study of Narcissism, sponsored by University of Washington.
- Active
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06565494 is a Early Phase 1 study of Narcissism that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06565494, a Early Phase 1 study of Narcissism, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This open-label, proof-of-concept pilot study will assess the efficacy and safety of midomafetamine (MDMA) - assisted therapy (AT) for participants diagnosed with pathological narcissism. As all participants will be allocated to a single group assignment, there will be no blinding, randomization, or comparator treatment. Participants will have a screening visit, a preparation period of 3 visits, a treatment period receiving MDMA-AT at 3 monthly visits, a 6 month follow up period coming in at one week, one month, three months and six months after last treatment visit.
Conditions Studied
Interventions
- DRUG midomafetamine (MDMA)-Assisted Therapy
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2027-01-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06565494
The ClinicalTrials.gov registry entry for NCT06565494 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Narcissism appearing as the primary indexed condition, and to 1 intervention - of which midomafetamine (MDMA)-Assisted Therapy is the first listed.
NCT06565494 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06565494 about?
NCT06565494 is a clinical study titled "MDMA-Assisted Therapy for Pathological Narcissism". This open-label, proof-of-concept pilot study will assess the efficacy and safety of midomafetamine (MDMA) - assisted therapy (AT) for participants diagnosed with pathological narcissism. As all participants will be allocated to a single group assignment, there will be no blinding, randomization, or...
What is the current status of trial NCT06565494?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2024-08-27. Estimated completion is 2027-01-31.
What conditions does trial NCT06565494 study?
This clinical trial studies the following conditions: Narcissism.
What interventions are being tested in trial NCT06565494?
The interventions under investigation include: midomafetamine (MDMA)-Assisted Therapy (DRUG).
Who is sponsoring clinical trial NCT06565494?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565494 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.